Source: American journal of nephrology. Unidade: FM
Subjects: NEFROPATIAS, DIABETES MELLITUS, FATORES DE RISCO
ABNT
BAKRIS, George L et al. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. American journal of nephrology, v. 50, n. 5, p. 333-344, 2019Tradução . . Disponível em: https://doi.org/10.1159/000503713. Acesso em: 09 nov. 2024.APA
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Nowack, C., et al. (2019). Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. American journal of nephrology, 50( 5), 333-344. doi:10.1159/000503713NLM
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, Kolkhof P, Ferreira AC, Schloemer P, Noronha I de L. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial [Internet]. American journal of nephrology. 2019 ; 50( 5): 333-344.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1159/000503713Vancouver
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, Kolkhof P, Ferreira AC, Schloemer P, Noronha I de L. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial [Internet]. American journal of nephrology. 2019 ; 50( 5): 333-344.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1159/000503713